CARA THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
CARA THERAPEUTICS INC. - More news...
CARA THERAPEUTICS INC. - More news...
- CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
- Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
- $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cara Therapeutics, Inc. - CARA
- CARA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cara Therapeutics, Inc. Is Fair to Shareholders
- Shareholder Alert: Ademi LLP Investigates Whether Cara Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
- SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics
- SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics
- Thinking about buying stock in Cara Therapeutics, RedHill Biopharma, Beyondspring, ATI Physical Therapy, or Co-Diagnostics?
- Thinking about buying stock in Xeris Pharmaceuticals, Cara Therapeutics, Bitfarms, Marathon Digital, or Pixelworks?
- SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics
- Thinking about buying stock in Cara Therapeutics, Romeo Power, Ardelyx, LG Display, or Peabody Energy?
- Cara Therapeutics Set to Join S&P SmallCap 600
- SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second Milestone Payment from Cara Therapeutics
- SWK Holdings' Subsidiary, Enteris BioPharma, Receives Milestone Payment from Cara Therapeutics
- Enteris BioPharma's Licensing Partner, Cara Therapeutics, Announces Top Line Data from Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for the Treatment of Pruritus in Patients with Advanced Chronic Kidney Disease (CKD)
-
Cara Therapeutics, Inc. - CARA Stock Chart Technical Analysis for 12-03-2019
- Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA™
- Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis
- Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Second Pruritus Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™
- Thinking about buying stock in Beyond Meat, Cara Therapeutics, Eltek, Plug Power, or Soliton?
- Consolidated Research: 2019 Summary Expectations for First Data, IDEXX Laboratories, CMS Energy, Worthington Industries, Triumph Group, and Cara Therapeutics — Fundamental Analysis, Key Performance Indications
- Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™
- Thinking about buying stock in Cara Therapeutics, Lowes, Neovasc Inc., Tiffany & Company or Target?
- Research Report Identifies Cara Therapeutics, MGE Energy, IDEXX Laboratories, Sterling Construction, TTM Technologies, and Regis with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
- Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Trial of Oral KORSUVA™
- Cara Therapeutics Inc to Host Earnings Call
- Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Study of Peptelligence™-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients
- Investor Network: Cara Therapeutics Inc to Host Earnings Call
- Investors: Covered Call reports for Cara Therapeutics, National Beverage Corp., Kraft Heinz Co, McDonald's and AT&T include trade ideas that offer returns of 25% or more!
- Today's stock options reports include trade ideas for Cara Therapeutics, Chemours Co, Dunkin' Brands, Trade Desk Inc and United Parcel Service
